Brief: Ix Biopharma Granted Orphan Drug Designation Granted For Treatment Of CRPS With Ketamine
17/05/2021 10:56
May 17 (Reuters) - IX Biopharma Ltd IXBI.SI :
* IX BIOPHARMA LTD. ORPHAN DRUG DESIGNATION GRANTED FOR THE
TREATMENT OF CRPS WITH KETAMINE TO IX BIOPHARMA
* IX BIOPHARMA LTD - US FDA GRANTED CO ORPHAN DRUG
DESIGNATION
FOR TREATMENT OF PATIENTS WITH COMPLEX REGIONAL PAIN SYNDROME
WITH KETAMINE
Source text for Eikon: urn:newsml:reuters.com:*:nSNZ7C4QSC
Further company coverage: IXBI.SI
(Reuters.briefs@thomsonreuters.com)
Recent news on IX Biopharma
See all newsBrief: Ix Biopharma Confirms Orion Not Yet Obtained Licence From Nevada State Board Of Pharmacy
Brief: Ix Biopharma Says U.S. Govt Opens Emergency Pathway, Clears Path For Wafermine Application For EUA
Brief: IX Biopharma Says Co Will Undertake An Internal Restructuring Of Its Consumer Business
Brief: IX Biopharma To Issue 1 MLN New Shares To Anson Properties At S$0.4215 Per Share
Brief: IX Biopharma Says US Government Awards US$41 MLN Contract To Fund Development Of Wafermine